Actively Recruiting
Phase I Study of SYS6005 to Evaluate Safety and Effectiveness in Adults With Advanced Malignant Tumors
Led by CSPC Megalith Biopharmaceutical Co.,Ltd. · Updated on 2025-05-14
132
Participants Needed
1
Research Sites
73 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating SYS6005, an investigational drug, in adults with advanced malignant tumors, including both solid tumors and B-cell malignancies. This Phase I, open-label, multicenter study aims to assess the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of SYS6005. The study includes patients who have failed standard therapies or are intolerant to them, focusing on determining the maximum tolerated dose and recommended Phase 2 dose of SYS6005. The study consists of two phases a dose-escalation phase using an accelerated titration design across seven dose levels with 21-day cycles, and a dose-expansion phase where selected doses and tumor types are further explored. Participants receive SYS6005 intravenously on Day 1 of each 21-day cycle. Treatment continues until disease progression, unacceptable side effects, or other reasons for stopping. Dose adjustments are guided by a Safety Monitoring Committee. Participants will undergo safety monitoring including adverse event reporting, laboratory tests, and performance status evaluations. Efficacy is assessed using imaging studies. Blood samples are collected to study pharmacokinetics and immune responses, including anti-drug antibodies. Survival is followed quarterly until death or study completion. The study may last up to 12 months or longer depending on treatment duration and follow-up needs.
CONDITIONS
Brief Title
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
Research Team
C
Clinical Trials Information Group officer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here